About AnGes
AnGes is a publicly listed company based in Japan founded in 1999. It operates as a gene-based therapies for rare diseases are developed by AnGes. The company has 55 employees. AnGes has completed 1 acquisition, including Emendo Biotherapeutics. Its chief executive is Ei Yamada. Its website anges.co.jp draws about 21 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
AnGes was founded in 1999 and is headquartered in Ibaraki, Japan, within the biotechnology sector. Focus is placed on developing gene therapies for rare diseases, with Naglazyme commercialized as the first product for treating Mucopolysaccharidosis VI. The lead program involves hepatocyte growth factor plasmid to enhance blood circulation through vessel regeneration, targeting critical limb ischemia. Operations center on research and therapeutic advancement in this field.
- Headquarters Ibaraki, Japan
- Employees 55
- Stage Public
- SectorsHealthcare
- Website category Finance · Investing
- Email••••••••
- Website anges.co.jp
- Social LinkedIn
- Legal Name Anges. Inc.
- Annual Revenue$5.58 M (USD)35.81as on Dec 31, 2025
- Net Profit-$32.68 M (USD)81.79as on Dec 31, 2025
- EBITDA-$32.49 M (USD)11.26as on Dec 31, 2025
- Investors
- Employee Count55
- Investments & Acquisitions
Funding Insights of AnGes
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of AnGes with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2002 | – | Unspecified | – | – |
1 investors in total: 1 institutional.
Investors in AnGes
AnGes has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include BioFrontier Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Support is provided for life science ventures by BioFrontier. | 2001 | biofrontier.co.jp | Tokyo, Japan |
Investor details for AnGes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AnGes
1 people are tracked at AnGes (1 in leadership); the tracked headcount is 55.
| Name | Role | Group |
|---|---|---|
Ei Yamada | CEO & President | Leadership |
Complete people profiles for AnGes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of AnGes
AnGes is a publicly listed company on the TSE with ticker symbol 4563 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Sep 2002
- Listed onTSE: 4563
- Listed entityAnGes. Inc.
- Exchange sectorHealth technology
- ISINJP3127700007
- Share price33.00 JPY · 2026-10-14
- Market capitalisation13,371,501,709.00 JPY
- EPS (diluted, trailing year)-9.83 JPY
- Volume (last session)979,200
Financials of AnGes
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 874.1M JPY | -5.12B JPY | -5.09B JPY |
| 2024 | 643.6M JPY | -28.13B JPY | -5.74B JPY |
| 2023 | 153.0M JPY | -7.44B JPY | -8.86B JPY |
| 2022 | 67.1M JPY | -14.71B JPY | -13.41B JPY |
| 2021 | 64.2M JPY | -13.68B JPY | -13.21B JPY |
Detailed financial statements for AnGes
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AnGes
AnGes has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Emendo Biotherapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Re-designed gene-editing tools are developed for genetic disorders. | emendobio.com | Ness Ziona, Israel | 2015 | Dec 2020 | •••• |
Complete acquisition details for AnGes
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of AnGes
4 dated milestones of AnGes across 21 years, from founding to its latest funding, stage changes and deals.
- Founded AnGes is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Emendo Biotherapeutics.
Competitors of AnGes
AnGes has 9 listed competitors in our database, 9 of them funded. They include Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. |
Detailed competitors of AnGes
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AnGes
The website of AnGes (anges.co.jp) receives about 21.4K visits a month and ranks #1,072,015 among all websites worldwide, #9,544 in Investing.
- Monthly visits21.4K
▼ 1.1% vs previous month
- Unique visitors7.1K
per month
- Global rank#1,072,015
among all websites
- Category rank#9,544
Finance · Investing
- Bounce rate39%
- Pages per visit3.0
- Average visit1 min 33 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with AnGes. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
finance.yahoo.co.jp | finance.yahoo.co.jp | 100% | – | #530 | – |
finance.logmi.jp | finance.logmi.jp | 89% | – | #296,748 | – |
| fisco.co.jp | 54% | 71.9K | #788,015 | View details |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as AnGes (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anges
Complete news archive for AnGes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AnGes
AnGes was founded in 1999 and raised its 1st funding round 3 years after it was founded.
AnGes is headquartered in Japan. It is registered at Ibaraki, Japan.
Ei Yamada is the current CEO of AnGes.
AnGes has 55 employees.
Annual revenue of AnGes is $5.58M as on Dec 31, 2025.
AnGes was founded in 1999 and is headquartered in Ibaraki, Japan, within the biotechnology sector. Focus is placed on developing gene therapies for rare diseases, with Naglazyme commercialized as the first product for treating Mucopolysaccharidosis VI. The lead program involves hepatocyte growth factor plasmid to enhance blood circulation through vessel regeneration, targeting critical limb ischemia. Operations center on research and therapeutic advancement in this field.
AnGes's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, AnGes is publicly traded on TSE under the ticker symbol 4563.
AnGes has made 1 acquisition, including Emendo Biotherapeutics.
AnGes has 1 investor. Key investors include BioFrontier Partners.